Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L).

The ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH3; Edelfosine) has been shown to be a rapid inducer of apoptosis in human leukemic cells and has been considered as a promising drug in cancer treatment. Here we have found that ET-18-OCH3 induced apoptosis not only in human tumor cell lines but also in primary tumor cell cultures from cancer patients. Human leukemic cells were highly sensitive to ET-18-OCH3, whereas normal cells remained unaffected. Among the distinct modifications of the ET-18-OCH3 molecule assayed, we found that substitutions in positions sn-2 and sn-3 of the glycerol backbone resulted in a complete loss of its capacity to induce apoptosis, highlighting the importance of the molecular structure of ET-18-OCH3 in its apoptotic effect. Induction of apoptosis by ET-18-OCH3 was very well correlated with the uptake of this ether lipid. ET-18-OCH3-resistant 3T3 fibroblasts became sensitive and incorporated significant amounts of the ether lipid following transformation with the SV40 virus. ET-18-OCH3-induced apoptosis as well as ET-18-OCH3 uptake were not mediated through binding of the ether lipid to the platelet-activating factor receptor. Overexpression of bcl-2 or bcl-xL by gene transfer in the human erythroleukemic HEL cells abrogated apoptosis induced by ET-18-OCH3. ET-18-OCH3 did not affect the expression of bcl-2, bcl-xL, or bax in HEL and HL-60 human leukemic cells but induced expression of c-myc, an important effector of apoptosis in several systems. Thus, ET-18-OCH3 behaves as a potent and highly selective antitumor drug able to induce an apoptotic pathway of cell death in tumor cells but not in nonmalignant cells.

[1]  O. Westphal,et al.  Antitumoral and other biomedical activities of synthetic ether lysophospholipids. , 1990, Chemical immunology.

[2]  F. Mollinedo,et al.  Early and selective induction of apoptosis in human leukemic cells by the alkyl-lysophospholipid ET-18-OCH3. , 1993, Biochemical and biophysical research communications.

[3]  E. Thiel,et al.  Chemopurging of peripheral blood-derived progenitor cells by alkyl-lysophospholipid and its effect on haematopoietic rescue after high-dose therapy. , 1996, Bone marrow transplantation.

[4]  W. Vogler,et al.  Purging leukemic cells from simulated human remission marrow with alkyl-lysophospholipid. , 1987, Blood.

[5]  R. Coffey,et al.  Suramin inhibition of growth factor receptor binding and mitogenicity in AKR‐2B cells , 1987, Journal of cellular physiology.

[6]  H. Heuer,et al.  Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor. , 1990, Journal of Pharmacology and Experimental Therapeutics.

[7]  E. Modest,et al.  Unidirectional membrane uptake of the ether lipid antineoplastic agent edelfosine by L1210 cells. , 1993, Biochemical pharmacology.

[8]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[9]  L. Verdonck,et al.  Influence of serum levels on leukemic cell destruction by the ether lipid ET-18-OCH3. , 1995, Leukemia research.

[10]  J. Cleveland,et al.  Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. , 1991, Oncogene.

[11]  K. Jalink,et al.  Identification of a putative membrane receptor for the bioactive phospholipid, lysophosphatidic acid. , 1992, The EMBO journal.

[12]  F. Re,et al.  The induction of apoptosis is a common feature of the cytotoxic action of ether‐linked glycerophospholipids in human leukemic cells , 1994, International journal of cancer.

[13]  V. Lew,et al.  Suramin: a potent ATPase inhibitor which acts on the inside surface of the sodium pump. , 1973, Biochimica et biophysica acta.

[14]  F. Re,et al.  Induction of apoptosis in human leukemic cells by the ether lipid 1‐octadecyl‐2‐methyl‐RAC‐glycero‐3‐ phosphocholine. A possible basis for its selective action , 1993, International journal of cancer.

[15]  W. Berdel,et al.  Removal of breast cancer cells from bone marrow by in vitro purging with ether lipids and cryopreservation. , 1993, Cancer research.

[16]  M. Erisman,et al.  Structure and expression of the oncogene c-myc in fresh tumor material from patients with hematopoietic malignancies , 1984, Molecular and cellular biology.

[17]  M. Rola-Pleszczynski,et al.  Human PAF receptor gene expression: induction during HL-60 cell differentiation. , 1991, Biochemical and biophysical research communications.

[18]  C. Rock,et al.  Lysophosphatidylcholine attenuates the cytotoxic effects of the antineoplastic phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3- phosphocholine , 1995, The Journal of Biological Chemistry.

[19]  T. Dexter,et al.  Role of endocytosis in the action of ether lipids on WEHI-3B, HL60, and FDCP-mix A4 cells. , 1990, Cancer research.

[20]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[21]  Z. Oltvai,et al.  Bcl-2 functions in an antioxidant pathway to prevent apoptosis , 1993, Cell.

[22]  A. Morris,et al.  Rapid intracellular calcium changes in U937 monocyte cell line: transient increases in response to platelet-activating factor and chemotactic peptide but not interferon-gamma or lipopolysaccharide. , 1987, Immunology.

[23]  U. Wollert,et al.  Spectroscopic studies on the complex formation of suramin with bovine and human serum albumin. , 1976, Biochimica et biophysica acta.

[24]  F. Mollinedo,et al.  The ether lipid 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine induces expression of fos and jun proto-oncogenes and activates AP-1 transcription factor in human leukaemic cells. , 1994, The Biochemical journal.

[25]  W. Berdel,et al.  Autologous bone marrow transplantation with alkyl-lysophospholipid-purged marrow. , 1993, Journal of hematotherapy.

[26]  R. Andreesen,et al.  Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids. , 1979, Cancer research.

[27]  F. Mollinedo,et al.  Differences in expression of transcription factor AP-1 in human promyelocytic HL-60 cells during differentiation towards macrophages versus granulocytes. , 1993, The Biochemical journal.

[28]  F. Snyder,et al.  HL-60 cells become resistant towards antitumor ether-linked phospholipids following differentiation into a granulocytic form. , 1988, Biochemical and biophysical research communications.

[29]  D. Kunz,et al.  The human leukocyte platelet-activating factor receptor. cDNA cloning, cell surface expression, and construction of a novel epitope-bearing analog. , 1992, The Journal of biological chemistry.

[30]  M. Clarke,et al.  The Bcl-2 family of proteins: regulators of cell death and survival. , 1994, Trends in cell biology.

[31]  David L. Vaux,et al.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.

[32]  A. Feinberg,et al.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. , 1983, Analytical biochemistry.

[33]  W. Vogler,et al.  Bone marrow purging in acute leukemia with alkyl-lysophospholipids: a new family of anticancer drugs. , 1994, Leukemia & lymphoma.

[34]  E. Modest,et al.  Animal cell mutants unable to take up biologically active glycerophospholipids. , 1995, Journal of lipid research.

[35]  C. Heldin,et al.  Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Green,et al.  Apoptotic cell death induced by c-myc is inhibited by bcl-2 , 1992, Nature.

[37]  G. Evan,et al.  Cooperative interaction between c-myc and bcl-2 proto-oncogenes , 1992, Nature.

[38]  S. Korsmeyer,et al.  Molecular thanatopsis: a discourse on the BCL2 family and cell death. , 1996, Blood.